Core Viewpoint - Guangji Pharmaceutical announced that its subsidiary, Hubei Huisheng Pharmaceutical Co., Ltd., has received the approval from the Hubei Provincial Drug Administration for the re-registration of the chemical raw material Vitamin B6 [1] Group 1 - The approval includes a notification for the chemical raw material Vitamin B6, which is used in the production of Vitamin B6 tablets and injections [1]

Group 1 - Dongli Machinery participated in the 2025 China Automobile Off-Road Rally Championship and won the T2.3 group championship as a club team [1] - The Arnoda-Black Bear Tire Chery Racing Team secured the T1.1 group championship [1] - Great Wall Haval Team, using Dongli Machinery's "Taihang Water" brand shock absorbers, achieved victories in the T2.1 and T2.E groups [1] Group 2 - Guangji Pharmaceutical's subsidiary, Hubei Huisheng Pharmaceutical Co., Ltd., received approval from the Hubei Provincial Drug Administration for the re-registration of the chemical raw material drug Vitamin B6 [1] - The raw material is intended for the production of Vitamin B6 tablets and Vitamin B6 injections [1]

Core Viewpoint - Guangji Pharmaceutical (000952) announced that its subsidiary, Hubei Huisheng Pharmaceutical Co., Ltd., has received the approval from the Hubei Provincial Drug Administration for the re-registration of the chemical raw material Vitamin B6 [1] Group 1 - The approved raw material is intended for the production of Vitamin B6 tablets and Vitamin B6 injection [1]

Group 1 - Dongli Machinery participated in the 2025 China Automobile Off-Road Rally Championship and won the T2.3 group championship as a club team [1] - The Arnoda-Black Bear Tire Chery Racing Team secured the T1.1 group championship [1] - Great Wall Haval Team, using Dongli Machinery's "Taihang Water" brand shock absorbers, won championships in the T2.1 and T2.E groups with a total of five vehicles [1] Group 2 - Guangji Pharmaceutical's subsidiary, Hubei Huisheng Pharmaceutical Co., Ltd., received approval from the Hubei Provincial Drug Administration for the re-registration of the chemical raw material drug Vitamin B6 [1] - The raw material is intended for the production of Vitamin B6 tablets and Vitamin B6 injection solutions [1]

Group 1 - The core point of the article is that Guangji Pharmaceutical's subsidiary, Hubei Huisheng Pharmaceutical Co., Ltd., has received approval for the re-registration of its chemical raw material Vitamin B6 from the Hubei Provincial Drug Administration, ensuring the stability and continuity of its production and sales qualifications [1] Group 2 - Vitamin B6 is used as a raw material for the production of Vitamin B6 tablets and injections, indicating its importance in the pharmaceutical industry [1] - The approval of the re-registration certificate is crucial for maintaining the company's operational capabilities in the Vitamin B6 market [1]

Group 1 - The core point of the article is that Guangji Pharmaceutical (000952.SZ) announced that its subsidiary, Hubei Huisheng Pharmaceutical Co., Ltd., received the approval notice for the re-registration of the chemical raw material Vitamin B6 from the Hubei Provincial Drug Administration [1] - The approval ensures the stability and continuity of the production and sales qualifications for Vitamin B6, which is used in the production of Vitamin B6 tablets and injections [1]

登记号：Y20190005296 受理号：CYHZ2545003 鄂 证券代码：000952 证券简称：广济药业 公告编号：2025-049 湖北广济药业股份有限公司 关于收到化学原料药再注册批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 湖北广济药业股份有限公司控股子公司湖北惠生药业有限公司（以下简称 "惠生公司"）于近日收到湖北省药品监督管理局核准签发的关于惠生公司化学 原料药维生素 B6 的《化学原料药再注册批准通知书》。现将相关情况公告如下： 一、《化学原料药再注册批准通知书》主要信息 化学原料药名称：通用名称：维生素 B6 英文名/拉丁名：Vitamin B6 通知书编号：2025R086000 化学原料药注册标准编号：《中国药典》2020 年版二部、《药品注册标准》 YBY64982024 原批准文号：国药准字 H42020121 包装规格：25kg/箱、25kg/桶 有效期：36 个月 生产企业：中文名称：湖北惠生药业有限公司 地址：湖北省咸宁市经济开发区长江产业园龟山路 33 号 通知书有效期：至 2030 年 09 月 16 ...

Core Viewpoint - Hubei Guangji Pharmaceutical Co., Ltd. has successfully completed the capital increase and business registration changes for its wholly-owned subsidiary, Hubei Guanghua Pharmaceutical Co., Ltd., by introducing strategic investors through a public listing process [1][2][3] Group 1: Transaction Overview - The capital increase involved introducing strategic investors, with a total registered capital increase of RMB 25 million [2] - The strategic investors identified are Hubei Changjiang Medical Industry Investment Co., Ltd. and Huanggang High-tech Industry Investment Group Co., Ltd., contributing RMB 200 million and RMB 50 million respectively [2][3] Group 2: Progress of the Transaction - As of the announcement date, Guanghua Pharmaceutical has completed the business registration changes and received the business license from Huanggang Market Supervision Administration [3][4] - Following the capital increase, Guanghua Pharmaceutical's registered capital is now RMB 35 million, with Changjiang Medical holding 57.14% and Huanggang High-tech holding 14.29% of the shares [4]

Group 1 - The core point of the article is that Guangji Pharmaceutical announced the confirmation of strategic investors for its wholly-owned subsidiary, Hubei Guanghua Pharmaceutical Co., Ltd. [1] - Hubei Guanghua Pharmaceutical has completed the capital increase and industrial and commercial change registration procedures [1] - The strategic investors identified are Hubei Changjiang Medical Industry Investment Co., Ltd. and Huanggang High-tech Industry Investment Group Co., Ltd. [1]

证券代码：000952 证券简称：广济药业 公告编号：2025-048 湖北广济药业股份有限公司 关于全资子公司湖北广化制药有限公司公开挂牌增资进展 暨完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 湖北广济药业股份有限公司（以下简称"公司"）全资子公司湖北广化制药 有限公司（以下简称"广化制药"）通过上海联合产权交易所（以下简称"上海 联交所"）征集并确认湖北省长江医疗产业投资有限公司（以下简称"长江医疗"） 及黄冈高新产业投资集团有限公司（以下简称"黄冈高投"）为其战略投资方。 近日，广化制药完成了增资和工商变更登记手续，现将相关情况公告如下： 一、交易概述 1.2024 年 11 月 15 日，公司全资子公司广化制药拟在上海联交所预挂牌， 通过增资扩股方式引入战略投资者。具体内容详见公司于 2024 年 11 月 16 日在 巨潮资讯网（http://www.cninfo.com.cn）、《中国证券报》《证券时报》《证 券日报》《上海证券报》披露的《关于全资子公司增资扩股事项预挂牌的提示性 公告》（公告编号：2024-072）。 ...